Clinical Trial Update: Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of bendamustine plus temsirolimus for relapsed or refractory mantle cell lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Torisel (Temsirolimus)
• Treanda (Bendamustine)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Mantle Cell Lymphoma | Phase 1, Phase 2 | Status: WITHDRAWN